Nationwide Study Finds HIV-Positive Women Are At High Risk For Cervical Human,,Papillomavirus Infection

In the largest study of its kind, a national team led by a UC San Francisco scientist has found strong new evidence that HIV-positive women run a high risk of infection with human papillomavirus (HPV), a major cause of cervical cancer. Women who already harbor the HIV virus are, on average, twice as likely to be infected with HPV than are high-risk HIV-negative women, the researchers found. The odds jump to a ten-fold greater risk of HPV infection among the most immune-suppressed women.

Although HIV status was by far the single-greatest risk factor for infection with HPV, the large size of the study group enabled the researchers to determine many other risk factors that had eluded previous, much smaller studies. Younger women, African American women and those who currently smoke each face more than a 50 percent increased likelihood of HPV infection than women over 40, Caucasians and non-smokers respectively, the researchers found.

The findings appear in the February 3 issue of the Journal of the National Cancer Institute.

The study provides new support for the view that the increased HPV disease among HIV-positive women results from reactivation or persistence of previously acquired HPV rather than recent acquisition of the virus.

The study was conducted before protease inhibitors were in widespread clinical use. However, it is possible that HIV-positive women who gain a new lease on life through protease inhibitors and other potent new treatments may face increased risk that an HPV condition will lead to cervical cancer as they live longer.

"Cervical cancer may take many years to develop," explains Joel Palefsky, MD, associate professor of laboratory medicine at UCSF and leader of the study. "With powerful new treatments that allow them to live a longer life with HIV, women who also have HPV infections unfortunately may face a greater likelihood than before of developing this cancer if they do not regularly undergo the currently recommend

Contact: Wallace Ravven
University of California - San Francisco

Page: 1 2

Related biology news :

1. NIH launches first center in Nationwide Chemical Genomics Network
2. Nationwide organic standards to be launched Monday
3. UCSF Research Team Looking For Volunteers For Nationwide Study On Family Traits And Alcoholism
4. Study: Emission of smog ingredients from trees is increasing rapidly
5. Study explores gene transfer to modify underlying course of Alzheimers disease
6. Study reveals why eyes in some paintings seem to follow viewers
7. Study by Israeli scientists provides insight on DNA code
8. Study reveals first genetic step necessary for prostate cancer growth
9. Study of flu patients reveals virus outsmarting key drug
10. Study in Science reveals recreational fishing takes big bite of ocean catch
11. Study suggests cell-cycle triggers might be cancer drug targets

Post Your Comments:

(Date:7/2/2020)... ... July 01, 2020 , ... ... phase 1a findings of Neihulizumab, a biologic for the treatment of steroid-refractory acute ... Led by hemato-oncologist Dr. Paul J Martin of the Fred Hutchinson Cancer Research ...
(Date:7/1/2020)... ... July 01, 2020 , ... Cure Glioblastoma, ... glioblastoma—the most common and aggressive adult brain cancer—announced today the appointments of its ... are charged with supporting the organization’s initiatives and overall vision. , "Senior Fellows ...
(Date:6/25/2020)... ... June 24, 2020 , ... ... software and software-driven clinical data services that accelerate drug development, is collaborating with ... an XPO1 inhibitor, in hospitalized patients with severe COVID-19. This is the first ...
Breaking Biology News(10 mins):
(Date:7/18/2020)... , ... July 17, 2020 , ... ... consulting firm for the life sciences and food industries, is pleased to announce ... of Clinical Research – Business Development. , Charles is an accomplished and results-driven ...
(Date:7/10/2020)... ... July 09, 2020 , ... ... today announced the hiring of Allen R. Nissenson, M.D., F.A.C.P., as its Chief ... clinical development of Sentien’s lead product, SBI-101. Dr. Nissenson serves as an ...
(Date:7/1/2020)... ... 29, 2020 , ... The Interlocal Purchasing System (TIPS), a ... recently named BioFit Engineered Products an Awarded Vendor. Awarded Vendor status ... cafeteria tables, book trucks and carts at discounted pricing without the delay and ...
(Date:6/28/2020)... ... June 25, 2020 , ... ... therapy for treating cancer, today announced the company has entered a license agreement ... The agreement provides Lumeda globally exclusive rights to Roswell Park intellectual property surrounding ...
Breaking Biology Technology:
Cached News: